Chichasova N V, Kanevskaia M Z, Slobodina G A, Varshavskiĭ V A, Krel' O V, Krel' A A
Ter Arkh. 1991;63(5):97-101.
Analysis is made of the results of the treatment with parenteral (crysanol and myochrysine) and oral (ridaura) gold drugs as well as with small doses of D-penicillamine (DP) of patients suffering from rheumatoid arthritis with the signs of nephropathy. The latter ones were identified, respectively, in 18 out of 80 patients who began receiving treatment, in 17 out of 72, and in 16 out of 61 patients. The clinical, laboratory, instrumental and morphological manifestations of nephropathy are described and analysis of their dynamics under the treatment impact is provided. It is noted that these types of basic therapy produce a beneficial effect on the manifestations of rheumatoid nephropathy. That referred to a greater measure to the gold drugs than to the small doses of DP. The degree of counteracting the symptoms of renal pathology agreed well with a good clinical effect in respect to the articular syndrome and inflammatory responses of blood. Among patients receiving crysanol, iatrogenic nephropathy was recorded in 8.75% of cases, among those on ridaura, in 2.8%, and those on DP, in 8.2% of cases. The authors provide evidence for the use of gold drugs and DP in patients suffering from rheumatoid nephropathy.
对患有类风湿性关节炎且有肾病迹象的患者，采用肠胃外给药（金诺芬和硫代苹果酸金钠）、口服给药（瑞得）金制剂以及小剂量D-青霉胺（DP）进行治疗的结果进行了分析。在开始接受治疗的80名患者中，分别有18名、72名患者中的17名以及61名患者中的16名被确诊患有肾病。文中描述了肾病的临床、实验室、仪器检查及形态学表现，并对其在治疗影响下的动态变化进行了分析。值得注意的是，这些类型的基础治疗对类风湿性肾病的表现产生了有益效果。与小剂量DP相比，金制剂的效果更为显著。对抗肾脏病理症状的程度与关节综合征及血液炎症反应方面良好的临床效果高度相符。在接受金诺芬治疗的患者中，医源性肾病的发生率为8.75%，接受瑞得治疗的患者中为2.8%，接受DP治疗的患者中为8.2%。作者为类风湿性肾病患者使用金制剂和DP提供了依据。
